A pan-cancer analysis of HER2 index revealed transcriptional pattern for precise selection of HER2-targeted therapy
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A pan-cancer analysis of HER2 index revealed transcriptional pattern for precise selection of HER2-targeted therapy
Authors
Keywords
HER2-amplification, HER2-enriched subtype, Pan-cancer, Biomarker, Multi-omics analysis, Machine learning
Journal
EBioMedicine
Volume 62, Issue -, Pages 103074
Publisher
Elsevier BV
Online
2020-11-09
DOI
10.1016/j.ebiom.2020.103074
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Reactive stroma and trastuzumab resistance in HER2‐positive early breast cancer
- (2020) Amir Sonnenblick et al. INTERNATIONAL JOURNAL OF CANCER
- The force of HER2 – A druggable target in NSCLC?
- (2020) M. Jebbink et al. CANCER TREATMENT REVIEWS
- Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
- (2019) Funda Meric-Bernstam et al. LANCET ONCOLOGY
- Prevalence and role of HER2 mutations in cancer
- (2019) Emiliano Cocco et al. PHARMACOLOGY & THERAPEUTICS
- Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation
- (2018) Tathiane M. Malta et al. CELL
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
- (2018) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
- (2018) Y Wang et al. ANNALS OF ONCOLOGY
- Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations
- (2018) Kanika Bajaj Pahuja et al. CANCER CELL
- Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2–Positive Metastatic Bladder Cancer
- (2017) Thomas Powles et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
- (2017) Antonio Llombart-Cussac et al. LANCET ONCOLOGY
- Computational correction of copy number effect improves specificity of CRISPR–Cas9 essentiality screens in cancer cells
- (2017) Robin M Meyers et al. NATURE GENETICS
- Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy
- (2017) Debora Fumagalli et al. JAMA Oncology
- Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial
- (2016) M. V. Dieci et al. ANNALS OF ONCOLOGY
- TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer
- (2016) María F. Mercogliano et al. CLINICAL CANCER RESEARCH
- Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge
- (2016) Tiziana Triulzi et al. Future Oncology
- Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
- (2016) Lisa A. Carey et al. JOURNAL OF CLINICAL ONCOLOGY
- Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial
- (2016) Edith A. Perez et al. JNCI-Journal of the National Cancer Institute
- Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
- (2016) Andrea Sartore-Bianchi et al. LANCET ONCOLOGY
- Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial
- (2016) Edith A. Perez et al. JNCI-Journal of the National Cancer Institute
- Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer
- (2015) Amir Sonnenblick et al. BMC Medicine
- Pharmacogenomic agreement between two cancer cell line data sets
- (2015) Nicolas Stransky et al. NATURE
- TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data
- (2015) Antonio Colaprico et al. NUCLEIC ACIDS RESEARCH
- HER2 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma
- (2014) Netanya I. Pollock et al. CLINICAL CANCER RESEARCH
- Oncogenic Alterations in ERBB2/HER2 Represent Potential Therapeutic Targets Across Tumors From Diverse Anatomic Sites of Origin
- (2014) J. Chmielecki et al. ONCOLOGIST
- RTCGAToolbox: A New Tool for Exporting TCGA Firehose Data
- (2014) Mehmet Kemal Samur PLoS One
- GSVA: gene set variation analysis for microarray and RNA-Seq data
- (2013) Sonja Hänzelmann et al. BMC BIOINFORMATICS
- PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers
- (2012) Roy RL Bastien et al. BMC Medical Genomics
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ER - breast cancer
- (2012) J. C. Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Molecular signatures database (MSigDB) 3.0
- (2011) A. Liberzon et al. BIOINFORMATICS
- GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers
- (2011) Craig H Mermel et al. GENOME BIOLOGY
- Wnt/β-Catenin Pathway Activation Is Enriched in Basal-Like Breast Cancers and Predicts Poor Outcome
- (2010) Andrey I. Khramtsov et al. AMERICAN JOURNAL OF PATHOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- The landscape of somatic copy-number alteration across human cancers
- (2010) Rameen Beroukhim et al. NATURE
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
- (2009) Joel S. Parker et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search